Analytical Support for High Potent Drug Development
Background on high potent molecules: High potent active pharmaceutical ingredients (HPAPIs) are drug substances characterized by high pharmacological or toxicological effect at very low doses. These molecules are increasingly common in oncology, targeted therapies, and highly specific modulators of receptors and enzymes. Though they offer significant therapeutic benefits, they pose unique risks related to occupational exposure, analytical sensitivity, and product quality control. As a result, their development requires specialized analytical expertise, dedicated containment facilities and robust safety controls, along with well-trained analytical teams.
The growing pipeline of high-potency compounds has increased demand for CDMOs capable of providing end-to-end analytical support while ensuring compliance with global regulatory expectations and strict safety standards.
Project objectives: This case study emphasizes end-to-end support provided by our analytical team for high-potent drugs progressing from lead optimization into formulation development. To achieve this the project was structured as below:
Conduct forced degradation studies: The goal is to generate degradation products to validate the analytical method that can separate the API from its breakdown products, thereby confirming stability. They include:
Hydrolysis: Acidic and Basic conditions
Oxidation: Treatment with Oxidizing agent
Photolysis: Exposure to UV and visible light per ICH Q1B guidelines.
Thermal: Dry heat and humid heat
Developing Stability-Indicating Methods (SIM) For stability studies, stability-indicating chromatographic methods are employed that could separate the active ingredient from impurities, degradants and potential genotoxic species at very low levels.
Formulation support: Analytical data were used in real time to guide formulation scientists in selecting excipients, container–closure systems, and process conditions that minimized degradation and preserved potency.
Safety Handling Procedures for High-Potent Molecules: Given the potent nature of the molecule, safety was integrated into every stage of analytical development.
Dedicated analytical laboratories for high-potency compounds: All analytical work was performed in dedicated high-potency laboratories equipped with:
Closed and contained analytical systems
Local exhaust ventilation and negative pressure environments
Specialized balances, sample preparation tools, and chromatographic systems designed for containment
Standard operating procedures (SOPs): Comprehensive SOPs were implemented at every step covering
From material receipt and storage
Sample preparation and transfer
Instrument cleaning and waste disposal
Emergency spill management
Personnel followed strict PPE requirements, including protective gowns, gloves, respirators, and eye protection, supported by appropriate engineering controls
Risk assessment and training protocols: Before method development or new studies, cross‑functional risk assessments are evaluated to identify exposure risks and mitigation strategies. Analysts underwent specialized training programs focused on handling high-potency materials, safe analytical practices, and waste management procedures.
Sample Handling and Waste Disposal: Samples were handled using closed systems wherever possible. All waste materials, including solvents and consumables, were disposed by following validated containment and hazardous waste disposal procedures, ensuring environmental and personnel safety.
API Analytical Methods Employed: The initial step focused on building a strong analytical foundation for high potent molecule.
Initial assay development: SmaBio employed HPLC/UV and LC–MS– based methods for assay, related substances, and impurity profiling, with particular attention to sensitivity and specificity at low concentration ranges.
Designing for sensitivity: Due to high molecule potency, methods were optimized to achieve low limits of detection (LOD) and quantitation (LOQ). Sample preparation techniques minimized dilution while maintaining analyst safety.
Forced degradation studies were conducted to evaluate the intrinsic stability of the API under:
Oxidative conditions
Hydrolytic conditions (acidic and basic)
Thermal stress
Photolytic stress These studies ensured identification of potential degradation pathways and ensured that the analytical methods could effectively separate the API from its degradants.
Validation in line with ICH expectations: The final methods were validated for specificity, linearity, accuracy, precision, range, LOD, and LOQ, ensuring fitness for both development and eventual regulatory submissions.
Forced Degradation and Stability Studies: Forced degradation studies were performed to:
Understand degradation mechanisms
Support method specificity
Establish stability-indicating capability
Stress conditions: The API was tested under thermal, oxidative, hydrolytic (acid/base), and photolytic conditions, using controlled, documented stress designs.
Identification of degradation pathways: Mapping degradation pathways was performed with various steps which include:
In Silico Prediction: A software was employed to predict likely breakdown of products based on the molecular structure.
Forced Degradation (Stress Testing): Subjected the molecule to "overstress" conditions
Chromatographic Separation: Used a Stability-Indicating Method (SIM) on HPLC or UHPLC to separate the API from its new "impurity" peaks.
Structural Elucidation: This was achieved by LC-MS/MS or NMR spectroscopy.
Analytical challenges: One of the key challenges was detecting trace-level degradants due to:
Extremely low dose strength
Stringent safety-driven dilution limits
This was addressed through:
Highly sensitive detection techniques
Optimized chromatographic conditions
Drug Product Analytical Methods: Formulation support: Using the identified degradation pathways, formulation support focused on selecting excipients to stabilize the HPAPI.
Release and stability testing: This includes routine methods to determine the presence of various impurities and micro-organisms. The common tests used here are:
Microbiological Safety: These tests include sterility and endotoxin tests to ensure the product is free from living microorganisms and the toxic byproducts they leave behind.
Chemical Potency: This is the core of the Stability-Indicating Method (SIM) which include following testing procedures:
Assay: A quantitative measure of the API concentration. It confirms the "potency" remains within limits (...)
Impurity Profiling: This is the most critical part of stability testing. It tracks the growth of degradation products over time.
Analytical goal alignment: All analytical activities were aligned with relevant ICH guidelines:
ICH Q1A – Stability testing
ICH Q2 – Analytical method validation
ICH Q3A/Q3B – Impurity control